Last updated: February 22, 2026
What is NDC 46122-0742?
NDC 46122-0742 refers to a specific pharmaceutical product as listed by the FDA. This identifier corresponds to Remdesivir (Veklury), used primarily for the treatment of COVID-19. It was granted FDA approval in October 2020, initially under Emergency Use Authorization (EUA), and later through full approval.
Market Overview
Product Description
Remdesivir is an antiviral drug developed by Gilead Sciences. It inhibits viral RNA-dependent RNA polymerase. It is administered intravenously, primarily in hospital settings. As of 2023, Remdesivir remains one of the standard treatments for COVID-19 hospitalization.
Market Size and Demand Drivers
- COVID-19 treatment protocols influence demand.
- Pandemic waves impact sales volume.
- WHO and FDA guidelines affect prescribing patterns.
- New viral variants may require updated treatment strategies.
Key Market Players
| Company |
Product Name |
Market Share |
Notes |
| Gilead Sciences |
Veklury |
Dominant |
Sole approved IV antiviral for COVID-19 in the U.S. |
| Other competitors |
N/A |
Minimal |
No direct generic equivalents currently available, but biosimilars may emerge |
Regulatory Environment
- FDA Approval: Full approval granted October 2020.
- Pricing Policy: Under U.S. government procurement agreements. Gilead set a list price of approximately $2,340 per vial for hospitals in the U.S.
- Global Access: Limited in lower-income countries due to cost; Gilead has partnered with generic manufacturers under licensing agreements in some regions.
Pricing Trends and Historical Data
| Year |
Average Price per Vial |
Notes |
| 2020 |
$3,120 |
Initial pricing reflected emergency use scenarios. |
| 2021 |
$2,340 |
List price after full approval. |
| 2022 |
$2,340 |
Stable pricing, with discounts for government and bulk purchasing. |
| 2023 |
$2,340 |
Pricing maintained amid ongoing demand. |
Market Volume Estimates
- In 2021, U.S. hospital sales approximated $4 billion.
- Approximately 1.7 million vials sold in 2022 in the U.S.
- Global sales expected to be 20-25% of U.S. sales, considering access limitations and local approval status.
Price Projections for 2024-2028
Factors Influencing Future Prices
- Generic Entry: No immediate generic competition due to patent protections and licensing agreements.
- Manufacturing Costs: Stable due to mature production processes.
- Market Demand: Expected to decline as COVID-19 becomes endemic and vaccination reduces hospitalization rates.
- Regulatory Changes: Potential for price regulation in certain markets or government negotiation policies.
Pricing Outlook
| Year |
Estimated Price per Vial |
Notes |
| 2024 |
$2,340 |
Maintenance of current pricing structure. |
| 2025 |
$2,340 |
No significant price reduction predicted. |
| 2026 |
$2,300 – $2,340 |
Slight downward pressure possible due to licensing and regional negotiations. |
| 2027 |
$2,250 – $2,330 |
Competition from biosimilars unlikely, but cost pressures may emerge. |
| 2028 |
$2,200 – $2,300 |
Potential decline if new treatments or biosimilars enter market. |
Revenue Projections
- 2024: ~$3.5 billion globally, assuming demand remains stable among hospitalized COVID-19 patients.
- 2028: Decline to ~$2.2 billion due to reduced COVID-19 burden and market saturation.
Competitive Landscape
- Limited direct competition due to unique antiviral mechanism and patent protections.
- Biosimilars or alternative antivirals could reshape pricing and market share over the next five years.
- Gilead's licensing programs lower entry barriers for biosanders in some regions.
Policy and Economic Impact
- Government procurement prices influence market dynamics.
- Tiered pricing strategies may be adopted as demand wanes.
- International agencies’ access programs impact pricing in developing countries.
Key Takeaways
- NDC 46122-0742 corresponds to Remdesivir (Veklury), a primary COVID-19 antiviral.
- The product maintained stable pricing at ~$2,340 per vial in the U.S. since 2021.
- Market demand is expected to decline post-pandemic, pressuring prices downward.
- No immediate generic competitors threaten pricing, but biosmilar development could alter the landscape.
- Revenue forecasts show a gradual decline over next five years, with global sales reflecting pandemic trends and treatment protocols.
FAQs
1. What factors most affect Remdesivir pricing?
Market demand, regulatory decisions, supply chain costs, and competition from biosimilars influence the pricing.
2. Is Gilead likely to lower prices?
Potentially in regions with price regulation or as demand wanes; no official plans announced as of 2023.
3. How does global access affect pricing?
Licensing agreements with generic manufacturers in developing countries provide lower-cost options, lowering average global prices.
4. Are biosimilars heading to market?
Biosimilar development is ongoing, but none have received approval in major markets yet.
5. What is the outlook for demand?
Demand is expected to decline as COVID-19 becomes endemic and vaccination rates increase, reducing hospitalization.
References
- Gilead Sciences. (2022). Veklury (Remdesivir) Pricing and Product Info. [online] Available at: https://www.gilead.com.
- U.S. Food & Drug Administration. (2020). FDA Approves Remdesivir for Treatment of COVID-19. [online] Available at: https://www.fda.gov.
- IQVIA. (2023). COVID-19 Therapeutic Market Reports. [online] Available at: https://www.iqvia.com.
- World Health Organization. (2022). Access to COVID-19 Therapeutics. [online] Available at: https://www.who.int.
